Search

Displaying results 3561 - 3570 of 5925 in total
  1. Drug

    Menaquinone 7

    go.drugbank.com/drugs/DB13075
    Investigational

    Menaquinone 7 is under investigation in clinical trial NCT00402974 (The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children).

    Mixtures: YYUX Organic Liquid Vitamin D3 plus K2 Drops
  2. Drug

    QR-1123

    go.drugbank.com/drugs/DB17869
    Investigational

    QR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (_RHO_) gene.[L46782]

  3. Drug

    10-hydroxycamptothecin

    go.drugbank.com/drugs/DB12385
    Experimental

    10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).

  4. Drug

    Iomethin I-131

    go.drugbank.com/drugs/DB21079
    Experimental

    Iomethin I-131 has a monoisotopic molecular weight of 359.06 Da.

  5. Drug

    Beclamide

    go.drugbank.com/drugs/DB09011
    Experimental

    Beclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity. It was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures.

  6. Drug

    Denifanstat

    go.drugbank.com/drugs/DB17576
    Investigational

    Due to its antineoplastic activities, it is being investigated for various cancers.

  7. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox.

  8. Drug

    Stiripentol

    go.drugbank.com/drugs/DB09118
    ApprovedInvestigational

    [A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes.

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  9. Drug

    Ceftobiprole medocaril

    go.drugbank.com/drugs/DB14733
    Approved

    Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due

  10. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    Due to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition. … Due to the risk of bone fractures that may lead to morbidities and reduced quality of life, the management of osteoporosis in postmenopausal women with the use of therapeutic agents in addition to concurrent

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 Inhibitors